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One important aim in cancer treatment is to 
kill cancer cells to control tumor growth and achieve 
remission. However, cancer cells have strong capability 
to adapt to hostile environment and evolve under stress. 
This posts a major challenge to the treatment as most of 
current therapeutic strategies fail to address how to prevent 
cancer cells from evolution while trying to kill them. The 
outcome of such therapeutic strategies is the emergence 
of harder-to-treat malignancies once they relapse. This 
has been clearly recognized in targeted cancer therapy 
using tyrosine kinase inhibitors [1]. For instance, chronic 
myelogenous leukemia (CML) can be effectively treated 
with imatinib mesylate, an inhibitor of BCR-ABL 
tyrosine kinase that causes the disease. However, CML 
cells, especially those in advanced phases of the disease, 
can rapidly develop resistance by acquisition of genetic 
mutations of BCR-ABL that in turn require stronger 
inhibitors to treat. Acquisition of genetic mutations of the 
targeted oncogenes or their closely related genes widely 
occurs in targeted cancer therapy [1]. Understanding the 
mechanisms how cancer cells evolve under therapeutic 
stress may help devise new strategies to improve cancer 
treatment. 
In a recent study, Wang et al showed that mammalian 
stress response gene SIRT1 is a key player promoting 
acquisition of genetic mutations for CML drug resistance 
[2]. SIRT1 encodes a protein deacetylase that deacetylates 
histones and non-histone proteins for diverse cellular 
functions including DNA damage repair.  In the model 
system the authors used, BCR-ABL mutations are acquired 
through a de novo process that is dependent on BCR-
ABL expression [3]. SIRT1 inhibition by small molecule 
inhibitors or gene knockdown blocks de novo acquisition 
of BCR-ABL mutations in blast crisis CML cells and 
prevents CML cell relapse from imatinib treatment.  Two 
more recent reports have shown that SIRT1 is activated 
by BCR-ABL in both kinase dependent and independent 
manners, and that SIRT1 activation promotes BCR-ABL 
mediated leukemogenesis and CML stem/progenitor cell 
survival from imatinib treatment [4, 5]. The study by Wang 
et al provides new insight that SIRT1 pathway may remain 
active after BCR-ABL kinase activity is inhibited and 
mediate subsequent acquisition of genetic mutations under 
imatinib therapeutic stress. The effect of SIRT1 is not 
limited to BCR-ABL and CML cells, as SIRT1 inhibition 
also effectively suppresses de novo mutation acquisition of 
HPRT (hypoxanthine phosphoribosyl transferase) gene in 
CML and prostate cancer cells when they are treated with 
the chemotherapeutic agent camptothecin.  Interestingly, 
the authors showed that the role of SIRT1 in promoting 
mutation acquisition is associated with its ability to 
enhance aberrant DNA damage repair, in particular, the 
error-prone non-homologous end joining (NHEJ) repair.
The findings by Wang et al apparently contrast with 
previous reports that SIRT1 maintains genome integrity 
[6, 7], which would predict that loss of SIRT1 could 
increase genetic instability and mutagenesis.  Intriguingly, 
whereas chromosomal abnormality is observed in 
SIRT1-/- embryonic stem cells [6, 7], impaired DNA 
damage response is similarly observed in SIRT1-/- mouse 
embryonic fibroblasts [7] and in SIRT1 knockdown CML 
cells [2]. Furthermore, SIRT1 knockdown reduces the 
efficiency of NHEJ and homologous recombination repair 
in CML cells [2] and previously, osteosarcoma cells [6]. 
Therefore, one plausible explanation for the difference 
is that SIRT1 may play a role for genome maintenance 
in both normal and cancer cells; but, there may be an 
important distinction of SIRT1 functions in normal versus 
cancer cells in this regard.  In embryonic cells, loss of 
SIRT1 leads to gross chromosomal abnormality; however, 
cells bearing abnormal chromosomes may not survive. 
The impact of SIRT1 knockout on genome integrity 
in normal somatic cells has not been examined, but is 
expected less than in embryonic cells. This is supported 
by the fact that SIRT1-/- mice, once they survive from 
early developmental defect, do not exhibit the increased 
incidence of spontaneous tumors [4] and referenced 
therein.  In contrast to normal cells, roles of SIRT1 in 
cancer cells may be more complicated. SIRT1 may help 
cancer genome maintenance by increasing DNA damage 
repair in response to the increased production of reactive 
oxygen species as a result of tumorigenesis.  However, 
as the fidelity of DNA damage repair is compromised 
in cancer cells [8], new genetic mutations may arise as 
a consequence of misrepair. With the increased SIRT1 
expression in cancer cells to enhance survival, genetic 
mutations or chromosomal lesions may be better tolerated, 
allowing cells to bypass apoptosis. Chemotherapy likely 
accentuates this process and stimulates evolution of 
mutant cells in response to therapeutic stress. Wang et al 
showed that SIRT1 may promote cancer evolution through 
enhancing Ku70-mediated error-prone NHEJ repair [2].   
Interestingly, this process resembles adaptive mutations 
in bacteria induced by environmental stress, which is Oncotarget 2012; 3:  363-364 364 www.impactjournals.com/oncotarget
promoted by activation of stress response genes and error-
prone DNA damage repair [9].  It is provocative to suggest 
that stress-induced mutagenesis may be a conserved 
pathway from bacteria to certain mammalian (cancer) cells 
to survive hostile environment, which involves cellular 
stress response and error-prone DNA damage repair. 
Although molecular details how therapeutic stress 
signals mutation acquisition and cancer evolution are yet 
to be worked out, the findings by Wang et al have clear 
translational implication. Given the roles of SIRT1 in 
CML molecular pathobiology and drug resistance, SIRT1 
inhibition in combination with BCR-ABL inhibitors may 
not only help eradicate residual CML stem cells but also 
prevent them from acquiring resistant mutations and 
evolution. Such a strategy may benefit treatment of other 
types of malignancies as well.
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